Researchers Identify 3 Small-Molecule β-Arrestin Inhibitors, Opening a New GPCR Drug Design Site
Updated
Updated · Nature.com · Jun 24
Researchers Identify 3 Small-Molecule β-Arrestin Inhibitors, Opening a New GPCR Drug Design Site
2 articles · Updated · Nature.com · Jun 24
Summary
Three compounds—Cmpd-5, Cmpd-46 and Cmpd-64—directly bound β-arrestins and cut receptor recruitment by 35% to 94% across a broad GPCR panel, marking the first reported small-molecule inhibitors of the signaling proteins.
Screening 3,500 compounds yielded 26 candidates, and follow-up assays showed the lead molecules disrupted β-arrestin engagement while largely sparing G-protein coupling, with recruitment inhibition reaching about 77% and receptor internalization up to 93%.
Cell and tissue experiments linked that blockade to stronger G-protein signaling and weaker β-arrestin functions: cAMP rose to 282% of control, calcium responses to 490%, while ERK signaling, T-cell migration and β-arrestin-driven cardiomyocyte contractility were reduced.
A 3.47-angstrom cryo-EM structure showed Cmpd-5 binding an allosteric pocket in β-arrestin1's central crest, stabilizing an inactive-like conformation with an 8° interdomain twist that prevents full receptor engagement.
Because GPCRs span more than 800 genes and account for about one-third of FDA-approved drug targets, the study points to transducer-targeted, pathway-specific therapies beyond traditional receptor-focused pharmacology.
Scientists found a hidden 'off switch' on a master protein. What other 'undruggable' targets could this method now unlock?
By disabling a cell's natural safety brake, have scientists unlocked a new class of super-drugs or unleashed cellular chaos?
A new molecule fine-tunes the body's response to drugs like Ozempic. How soon could this revolutionize metabolic treatments?
First Direct β-Arrestin Inhibitors Discovered: Transforming "Undruggable" GPCR Targets and Precision Medicine (June 2026)
Overview
On June 24, 2026, Duke University researchers led by Nobel Laureate Robert J. Lefkowitz announced a major scientific breakthrough: the first small-molecule inhibitors that can directly target β-arrestins, proteins long considered 'undruggable.' This discovery builds on decades of research, starting with the identification of β-arrestins as regulators of G-protein coupled receptors (GPCRs) and later revealing their own unique signaling roles. By successfully developing compounds like Cmpd-5, Cmpd-46, and Cmpd-64, the team has opened new possibilities for drug development and future therapies targeting diseases linked to β-arrestin signaling.